Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: We performed a comparative analysis of the plasma levels of antithrombin (AT) III, plasminogen, fibrinogen, and D-dimer among patients with and without clinically localized prostate cancer to investigate the clinical significance of the coagulation profile in prostate cancer.
Materials and Methods: A prospective study was performed in which plasma levels of AT III, plasminogen, fibrinogen, and D-dimer were assessed in patients before they underwent prostate biopsy. According to the results of the biopsy, the patients were categorized into the cancer group or the control group. Levels of the four coagulation factors were then compared between the cancer and control groups. Also, levels of the four coagulation factors were correlated with tumor stage and grade in the cancer group.
Results: The cancer group had significantly lower levels of AT III activity and higher plasma D-dimer levels than did the control group (p=0.007 and p=0.018, respectively). Within the cancer group, no significant differences were observed in the levels of AT III, plasminogen, fibrinogen, or D-dimer between those with a pathological Gleason score of ≥7 and otherwise. Regarding pathologic stage of prostate cancer, the subjects with organ-confined disease and those with extraprostatic extension of a tumor demonstrated no significant differences in the preoperative levels of the four coagulation factors analyzed.
Conclusions: Our results suggest that plasma levels of AT III and D-dimer are altered in patients with prostate cancer. Further study is needed to elucidate the underlying mechanism and clinical significances of such a phenomenon among patients with clinically localized prostate cancer.

다국어 초록 (Multilingual Abstract)

Purpose: We performed a comparative analysis of the plasma levels of antithrombin (AT) III, plasminogen, fibrinogen, and D-dimer among patients with and without clinically localized prostate cancer to investigate the clinical significance of the coagulation profile in prostate cancer.
Materials and Methods: A prospective study was performed in which plasma levels of AT III, plasminogen, fibrinogen, and D-dimer were assessed in patients before they underwent prostate biopsy. According to the results of the biopsy, the patients were categorized into the cancer group or the control group. Levels of the four coagulation factors were then compared between the cancer and control groups. Also, levels of the four coagulation factors were correlated with tumor stage and grade in the cancer group.
Results: The cancer group had significantly lower levels of AT III activity and higher plasma D-dimer levels than did the control group (p=0.007 and p=0.018, respectively). Within the cancer group, no significant differences were observed in the levels of AT III, plasminogen, fibrinogen, or D-dimer between those with a pathological Gleason score of ≥7 and otherwise. Regarding pathologic stage of prostate cancer, the subjects with organ-confined disease and those with extraprostatic extension of a tumor demonstrated no significant differences in the preoperative levels of the four coagulation factors analyzed.
Conclusions: Our results suggest that plasma levels of AT III and D-dimer are altered in patients with prostate cancer. Further study is needed to elucidate the underlying mechanism and clinical significances of such a phenomenon among patients with clinically localized prostate cancer.

참고문헌 (Reference)

1 Browder T, "The hemostatic system as a regulator of angiogenesis" 275 : 1521-1524, 2000

2 Kohli M, "Role of coagulation and fibrinolytic system in prostate cancer" 29 : 301-308, 2003

3 Beecken WD, "Reduced plasma levels of coagulation factors in relation to prostate cancer" 53 : 160-167, 2002

4 Kilic M, "Prognostic value of plasma D-dimer levels in patients with colorectal cancer" 10 : 238-241, 2008

5 Unsal E, "Prognostic significance of hemostatic parameters in patients with lung cancer" 98 : 93-98, 2004

6 Caine GJ, "Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma" 92 : 185-190, 2004

7 Langer F, "Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers" 97 : 464-470, 2007

8 Dirix LY, "Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer" 86 : 389-395, 2002

9 Blackwell K, "Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status" 18 : 600-608, 2000

10 Falanga A, "Pathophysiology of the thrombophilic state in the cancer patient" 25 : 173-182, 1999

11 Donati MB, "Pathogenetic mechanisms of thrombosis in malignancy" 106 : 18-24, 2001

12 Oya M, "High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer" 31 : 388-394, 2001

13 Koh SC, "Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?" 7 : 141-148, 2001

14 Rickles FR, "Hemostatic alterations in cancer patients" 11 : 237-248, 1992

15 Constantini V, "Fibrin and cancer" 69 : 406-414, 1993

16 Bick RL, "Coagulation abnormalities in malignancy: a review" 18 : 353-372, 1992

17 Kim TH, "Choi H, et al. Evaluation of the changes of coagulation-fibrinolysis system during transurethral resection of the prostate by thromboelastography" 38 : 1217-1222, 1997

18 Shariat SF, "Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis" 25 : 349-355, 2007

19 Cao Y, "Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2" 161 : 2053-2063, 2002